Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Semin Oncol. 2013 Jun;40(3):347-60. doi: 10.1053/j.seminoncol.2013.04.009.
The goals of any cancer therapy are to improve disease control, palliate pain and improve overall survival. We are fortunate to have in our cancer armamentarium two new immune-directed therapies which not only impact on disease control but also on overall survival. The first, sipuleucel-T, a cellular-based vaccine, was approved for prostate cancer and was shown to be safe with minimal toxicity. The second, ipilimumab, a monoclonal antibody directed to an immunologic checkpoint molecule, showed a survival benefit in patients with advanced melanoma. Benefit appeared to correlate in some cases with the development of autoimmune events, signaling that the immune system is in overdrive against the cancer. Where we are and where we will likely go are the topics to be discussed in this review.
任何癌症治疗的目标都是改善疾病控制、缓解疼痛和提高总体生存率。我们很幸运地拥有两种新的免疫导向治疗方法，它们不仅影响疾病控制，而且影响总体生存。第一种是细胞疫苗 sipuleucel-T，已被批准用于前列腺癌，并且具有安全性，毒性极小。第二种是针对免疫检查点分子的单克隆抗体 ipilimumab，在晚期黑色素瘤患者中显示出生存获益。在某些情况下，获益似乎与自身免疫事件的发展相关，表明免疫系统过度攻击癌症。在这篇综述中，我们将讨论我们所处的位置以及我们可能会走向何方。
